Regina M. Paglia - Jun 22, 2021 Form 4 Insider Report for Dicerna Pharmaceuticals Inc (DRNA)

Signature
/s/ Douglas W. Pagan, attorney-in-fact
Stock symbol
DRNA
Transactions as of
Jun 22, 2021
Transactions value $
-$394,869
Form type
4
Date filed
6/24/2021, 09:25 PM
Previous filing
Jun 22, 2021
Next filing
Jun 29, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DRNA Common Stock Options Exercise $178K +13.8K +5111.52% $12.93 14K Jun 22, 2021 Direct
transaction DRNA Common Stock Options Exercise $51.5K +2.28K +16.26% $22.58 16.3K Jun 22, 2021 Direct
transaction DRNA Common Stock Options Exercise $57.9K +2.41K +14.76% $24.05 18.7K Jun 22, 2021 Direct
transaction DRNA Common Stock Sale -$503K -13.6K -72.47% $37.10 5.15K Jun 22, 2021 Direct F1, F2
transaction DRNA Common Stock Sale -$179K -4.88K -94.78% $36.71 269 Jun 22, 2021 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DRNA Employee Stock Option (Right to Buy) Options Exercise $0 -13.8K -13.92% $0.00 85K Jun 22, 2021 Common Stock 13.8K $12.93 Direct F4
transaction DRNA Employee Stock Option (Right to Buy) Options Exercise $0 -2.28K -4.34% $0.00 50.2K Jun 22, 2021 Common Stock 2.28K $22.58 Direct F5
transaction DRNA Employee Stock Option (Right to Buy) Options Exercise $0 -2.41K -4.18% $0.00 55.1K Jun 22, 2021 Common Stock 2.41K $24.05 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person sold an aggregate of 18,435 shares of Common Stock on June 22, 2021 (the "Shares Sold") as reported in this Form 4. The Shares Sold represent 7.75% of 237,824 shares of Common Stock, which is the number of shares of Common Stock owned by the Reporting Person prior to the Shares Sold transaction reported in this Form 4, as well as shares issuable upon exercise or settlement of vested and unvested options and restricted stock units held by the Reporting Person as of the date of this report.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $37.00 to $37.35, inclusive. The Reporting Person undertakes to provide to Dicerna Pharmaceuticals, Inc., any security holder of Dicerna Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
F3 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $36.625 to $36.865, inclusive. The Reporting Person undertakes to provide to Dicerna Pharmaceuticals, Inc., any security holder of Dicerna Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
F4 The option vested 25% on the first year anniversary of the vesting start date of February 19, 2019 and the remaining 75% vests in 36 substantially equal monthly installments thereafter, subject in each case to the Reporting Person's continued service with the Issuer through each applicable vesting date.
F5 The option vests in 48 substantially equal monthly installments, with the first installment vesting on the last day of January 2020, and the remaining vesting on the last day of each of the 47 months thereafter; subject in each case to the Reporting Person's continued service with the Issuer through each applicable vesting date.
F6 The option vests in 48 substantially equal monthly installments, with the first installment vesting on the last day of January 2021, and the remaining shares vesting on the last day of each of the 47 months thereafter; subject in each case to the Reporting Person's continued employment or service with the Issuer through each applicable vesting date.